Patents by Inventor Samuele Lillini

Samuele Lillini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230002302
    Abstract: The present invention refers to a eco-crystal of Ketoprofen Lysine named Form 4, a pharmaceutical composition comprising said co-crystal, a process for its preparation and to its use in the treatment of pain and Inflammatory diseases.
    Type: Application
    Filed: December 21, 2020
    Publication date: January 5, 2023
    Inventors: Andrea ARAMINI, GianÍuca BIANCHINI, Samuele LILLINI
  • Publication number: 20220071936
    Abstract: The present invention refers to a co-crystal of Ketoprofen Lysine named Form 1, a pharmaceutical composition comprising said co-crystal, a process for its production and to its use in the treatment of pain and inflammatory diseases.
    Type: Application
    Filed: December 20, 2019
    Publication date: March 10, 2022
    Inventors: Andrea ARAMINI, Gianluca BIANCHINI, Samuele LILLINI
  • Patent number: 11046662
    Abstract: The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). The compounds of the invention are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: June 29, 2021
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventors: Andrea Aramini, Gianluca Bianchini, Laura Brandolini, Andrea Beccari, Samuele Lillini, Giuseppe Nano
  • Publication number: 20190106395
    Abstract: The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.
    Type: Application
    Filed: December 6, 2018
    Publication date: April 11, 2019
    Inventors: Andrea ARAMINI, Gianluca Bianchini, Laura Brandolini, Andrea Beccari, Samuele Lillini, Giuseppe Nano
  • Patent number: 10246448
    Abstract: The invention relates to compounds acting as antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I): Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold-induced and/or exacerbated-respiratory disorders, urological disorders, corneal disorders associated to disturbances in the production of the tears and/or altered blinking such as epiphora and dry eye disease.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: April 2, 2019
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventors: Andrea Aramini, Gianluca Bianchini, Samuele Lillini
  • Patent number: 10196368
    Abstract: The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: February 5, 2019
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventors: Andrea Aramini, Gianluca Bianchini, Laura Brandolini, Andrea Beccari, Samuele Lillini, Giuseppe Nano
  • Publication number: 20180319785
    Abstract: The invention relates to compounds acting as antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I): Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold-induced and/or exacerbated-respiratory disorders, urological disorders, corneal disorders associated to disturbances in the production of the tears and/or altered blinking such as epiphora and dry eye disease.
    Type: Application
    Filed: December 16, 2016
    Publication date: November 8, 2018
    Inventors: Andrea ARAMINI, Gianluca BIANCHINI, Samuele LILLINI
  • Publication number: 20170190678
    Abstract: The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.
    Type: Application
    Filed: June 23, 2015
    Publication date: July 6, 2017
    Inventors: Andrea ARAMINI, Gianluca BIANCHINI, Laura BRANDOLINI, Andrea BECCARI, Samuele LILLINI, Giuseppe NANO
  • Patent number: 8268827
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: September 18, 2012
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA.
    Inventors: Danila Branca, Gabriella Dessole, Federica Ferrigno, Philip Jones, Olaf Kinzel, Samuele Lillini, Ester Muraglia, Giovanna Pescatore, Carsten Schultz-Fademrecht
  • Publication number: 20100261709
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinaldamage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.
    Type: Application
    Filed: November 14, 2008
    Publication date: October 14, 2010
    Inventors: Danila Branca, Gabriella Dessole, Federica Ferrigno, Philip Jones, Olaf Kinzel, Samuele Lillini, Ester Muraglia, Giovanna Pescatore, Carsten Schultz-Fademrecht